{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:38:10Z","timestamp":1794746290871,"version":"4.9.1"},"reference-count":0,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The place of long-acting \u03b2 agonist\/long-acting muscarinic antagonist (LABA\/LAMA) combinations in stable patients with COPD is not well defined. The purpose of this study was to systematically review the efficacy and safety of LABA\/LAMA combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Several databases and manufacturers\u2019 websites were searched for relevant clinical trials. Randomised control trials, at least 12\u2005weeks duration, comparing a LABA\/LAMA combination with placebo and\/or monotherapy were included. The data were pooled using a network as well as a traditional direct comparison meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-three trials with a total of 27\u2005172 patients were included in the analysis. LABA\/LAMA combinations were associated with a greater improvement in lung function, St. George's Respiratory Questionnaire (SGRQ) score, and Transitional Dyspnoea Index (TDI) than monotherapies. LABA\/LAMA combinations were associated with a significantly greater proportion of SGRQ and TDI responders than monotherapies (OR 1.23 (95% credible interval (CrI) 1.06\u20131.39), OR 1.34 (95% CrI 1.19\u20131.50) versus LABAs and OR 1.24 (95% CrI 1.11\u20131.36), OR 1.31 (95% CrI 1.18\u20131.46) versus LAMAs, respectively) and fewer moderate-to-severe exacerbations compared with LABAs (HR 0.82 (95% CrI 0.73\u20130.93)), but not when compared with LAMAs (HR 0.92 (95% CrI 0.84\u20131.00)). There were no statistically significant differences associated with LABA\/LAMA combinations compared with monotherapies in safety outcomes as well as in severe exacerbations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The combination therapy was the most effective strategy in improving lung function, quality of life, symptom scores and moderate-to-severe exacerbation rates, and had similar effects on safety outcomes and severe exacerbations as compared with monotherapies.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thoraxjnl-2014-206732","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T02:58:47Z","timestamp":1445482727000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":97,"title":["Efficacy and safety of long-acting \u03b2-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis"],"prefix":"10.1136","volume":"71","author":[{"given":"Yuji","family":"Oba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva T","family":"Sarva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,10,21]]},"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2014-206732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T05:50:45Z","timestamp":1601099445000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2014-206732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,21]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,16]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1136\/thoraxjnl-2014-206732"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206732","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,21]]}}}